ONO PHARMACEUTICAL CO.,LTD.

November 14, 2016

Amgen Receives Marketing Authorization Approval from European Commission for Parsabiv™ (Etelcalcetide) to Treat Patients with Secondary Hyperparathyroidism

On November 11, 2016, Amgen Inc. (NASDAQ:AMGN) announced that the European Commission today granted marketing authorization of Parsabiv™ (etelcalcetide) for the treatment of secondary hyperparathyroidism in adult hemodialysis patients with chronic kidney disease.

For further information, visit the link below to the website for press release distributed by Amgen.

http://www.amgen.com/media/news-releases/2016/11/european-commission-approves-parsabiv-etelcalcetide-for-the-treatment-of-secondary-hyperparathyroidism-in-adults-on-hemodialysis/

In Japan, ONO PHARMACEUTICAL CO., LTD.(“ONO”) has exclusive rights to develop and commercialize the agonist of calcium sensing receptor, etelcalcetide, in accordance with the license agreement concluded with KAI Pharmaceuticals, Inc., now a wholly-owned subsidiary of Amgen, in September 2011. ONO has filed a manufacturing and marketing approval application of etelcalcetide for the treatment of secondary hyperparathyroidism in patients with chronic kidney disease who receive hemodialysis in January 2016.

.

ONO PHARMACEUTICAL CO., LTD.
Corporate Communications
Public_relations@ono.co.jp